---
title: "ELDN: Tegoprubart shows superior efficacy and safety over tacrolimus in transplant trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295844935.md"
description: "Tegoprubart, a novel anti-CD40L antibody, demonstrated superior kidney function, reduced side effects, and improved patient-reported outcomes compared to tacrolimus in kidney and islet cell transplantation studies. The company is well-funded and advancing multiple Phase 3 and registrational trials across transplant indications.Original document: Eledon Pharmaceuticals, Inc. [ELDN] Slides Release — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-13T20:43:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295844935.md)
  - [en](https://longbridge.com/en/news/295844935.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295844935.md)
generator: "portal-rs"
---

# ELDN: Tegoprubart shows superior efficacy and safety over tacrolimus in transplant trials

Tegoprubart, a novel anti-CD40L antibody, demonstrated superior kidney function, reduced side effects, and improved patient-reported outcomes compared to tacrolimus in kidney and islet cell transplantation studies. The company is well-funded and advancing multiple Phase 3 and registrational trials across transplant indications.

Original document: Eledon Pharmaceuticals, Inc. \[ELDN\] Slides Release — Aug. 13 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ELDN.US](https://longbridge.com/en/quote/ELDN.US.md)

## Related News & Research

- [Eledon Pharmaceuticals Publishes Presentation on Patient-Reported Outcomes in Phase 2 BESTOW Trial](https://longbridge.com/en/news/303084572.md)
- [Eledon’s Tegoprubart Improves Quality of Life Versus Tacrolimus in Phase 2 Kidney Transplant Trial](https://longbridge.com/en/news/303071917.md)
- [Microsoft Just Revealed a $677 Billion Reason to Buy Its Stock](https://longbridge.com/en/news/303993065.md)
- [Eledon to present Phase 2 BESTOW kidney transplant trial patient-reported outcomes for tegoprubart at ASN Kidney Week 2026](https://longbridge.com/en/news/300964181.md)
- [Google Says Demand Will Swallow Every Data Center It Builds](https://longbridge.com/en/news/303998103.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**